Revenio Group Corporation: Changes to Revenio’s financial reporting schedule in 2019
Stock Exchange Release April 15, 2019 at 8.35 am
CHANGES TO REVENIO’S FINANCIAL REPORTING SCHEDULE IN 2019
As an update to the previously announced schedule, Revenio Group Corporation will publish its Interim Report for Q1/2019 and Half-year Financial Report for H1/2019 as follows:
- Interim Report Q1/2019 on Tuesday, April 16, 2019 (previously April 17, 2019)
- Half-year Financial Report H1/2019 on Thursday, August 15, 2019 (previously August 5, 2019)
Interim Report Q3/2019 according to the original schedule on Thursday, October 24, 2019.
Revenio Group Corporation
Board of Directors
For further information, please contact:
Timo Hildén, CEO, tel. +358 40 580 4774
timo.hilden@revenio.fi
www.revenio.fi
DISTRIBUTION:
Nasdaq Helsinki
Financial Supervisory Authority
Principal media
www.revenio.fi
The Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology.
The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy. Revenio’s core business is to develop and commercialize effective and easily adopted devices to assist in the diagnostics of glaucoma and and its monitoring during treatment.
Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio’s technology is on the early detection of glaucoma, skin cancer and asthma, and the monitoring of these during the treatment process.
In 2018, the Revenio Group's net sales totaled EUR 30.7 million, with its operating margin standing at 33.3%. Revenio Group Corporation is listed on Nasdaq Helsinki.